INTerpath-002: pembrolizumab with a neoantigen therapy in completely resected NSCLC

(1:21)

INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma

(1:22)

PEMMELA cohort 2: second line pembrolizumab and lenvatinib in PM

(55)

TU2218, a TGFβ-RI and VEGFR2 dual inhibitor, with pembrolizumab in solid tumors

(1:10)

Why Interpath Laboratory?

(3:26)

2024 Interpath Welcome to the Team

(6:35)

Interpath for iPhone

(1:11)

PARP inhibitor monotherapy

(5:6)

Interpath COVID 19 [2020]

(2:1econd)

Nagico and Interpath Junior CASA 2024

(2:12)

Interpath Laboratory: COVID-19 Update

(2:1econd)

2-year follow-up of MajesTEC-1: teclistamab in R/R multiple myeloma

(46)

Interpath Laboratory - Pendleton Roundup 2023

(37)

Lauren Goodenough (Interpath Advisory France) : Fusions et acquisitions au ralenti en 2024

(7:16)

IKCS 2020: Phase 2 trial of lenvatinib at 2 starting doses+ everolimus in renal cell carcinoma (RCC)

(10:55)

Emma Baylis - Managing Director - Interpath Advisory | Leaders with Ambition Ep. 51

(47:41)

Microstream™ Capnography Basics

(7:17)